Add Fetal RhD NIPT to Panorama™
Plan ahead for Rh negative patients who are alloimmunized or at risk
Vivienne Souter
MD MPH FACMG FACOG
Medical Director, Women's Health
The evolution of NIPT: what comes next
Fetal RhD NIPT to inform management of Rh negative pregnant patients
In this webinar Dr Vivienne Souter MD MPH will discuss RhD and its role in pregnancy, and review data from a large clinical validation study of Fetal RhD NIPT.
Get highly accurate fetal RhD NIPT
Natera’s Fetal RhD NIPT is backed by the largest fetal RhD NIPT clinical validation study with confirmed outcomes in the US.1 Add Fetal RhD to Panorama™ NIPT for Rh negative patients who are alloimmunized or at risk for alloimmunization.
655
Rh- patients
Sensitivity: 100%, 95% CI* (98.9-100%)
Fetal Rh+
n = 356/356
Specificity: 99.3%, 95% CI (97.6-99.8%)
Fetal Rh-
n = 295/297
In the validation study, fetal RhD status was reported for 99.7% of patients (n=653/655)
*CI=confidence interval. In clinical use false negatives and false positives are possible and may occur.
- Included a representative mix of race and ethnicities in the Rh negative US population
- Confirmed the test can identify the RhD pseudogene (RHDψ) and RHD-CE-D hybrid gene, most commonly occurring in people of non-European ancestries.
Perspectives on Natera’s Fetal RhD NIPT
Hear a practicing OB/GYN’s thoughts on the new Fetal RhD NIPT validation and its clinical utility
Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort
Watch Jeffrey T. Meltzer, MD, MBA, Senior Medical Director, review the clinical validation study for Natera’s Fetal RhD NIPT that was presented as a late-breaking abstract at the 2024 ACOG Annual Clinical and Scientific Meeting.
Inform decisions about RhD immune globulin
“…the use of NIPT to prioritize use of RhIg and conserve RhIg supply is a reasonable consideration in the practice setting that is experiencing RhIg shortages. Noninvasive fetal red blood cell antigen genotyping utilizing cell-free DNA (cfDNA) isolated from maternal plasma has demonstrated high sensitivity and specificity for detection of fetal Rh(D) antigen status”
ACOG Rho(D) Immune Globulin Shortages Practice Advisory, updated April 20242
Order with ease
Provide comprehensive prenatal screening with the #1 ordered NIPT and carrier screen5
- Order Fetal RhD NIPT on the same form with the Panorama™ Horizon™ Combo Kit
- No additional sample required
- Receive results on the Panorama™ report
Robust support for you and your patients
- Clear, actionable reports
- Broad in-network coverage and financial access programs for patients who qualify. Learn more
- Complimentary pre- and post-test genetic information sessions with Natera’s board-certified genetic counselors
- NEVA, Natera’s Educational Virtual Assistant, which provides 24-7 access to results in English and Spanish. Learn more.
Incorporate Fetal RhD NIPT for your pregnant patients
References
1Gilstrop Thompson et al. Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort. Obstet Gynecol. ():10.1097
2ACOG Rho(D) Immune Globulin Shortages Practice Advisory. March 2024, updated April 2024
Fetal RhD NIPT provides a genotyping test result that determines the RhD gene sequence associated with fetal RhD status for pregnant RHD- (negative) people. Fetal RhD genotype does not always correlate with the phenotype. Panorama™ and Fetal RhD NIPT have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). CAP accredited, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.